Cancer vaccine - PhotonPharma
Alternative Names: Innocell; Innocell Autologous Cellular Immunotherapy; Innocell Personalized Therapy; Innocell therapeutic vaccine; Innocell vaccineLatest Information Update: 05 Feb 2026
At a glance
- Originator Colorado State University
- Developer PhotonPharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ovarian cancer
- Preclinical Solid tumours
Most Recent Events
- 28 Jan 2026 Phase-I clinical trials in Ovarian cancer (Recurrent, Late-stage disease, Second-line therapy or greater) in USA (Intradermal) (NCT06366490)
- 16 Apr 2024 PhotonPharma plans a phase I trial for Ovarian cancer in June 2024 (NCT06366490)
- 05 Mar 2024 PhotonPharma plans a phase I trial for Ovarian cancer (Late-stage disease) in USA (Parenteral), in 2024